CpH methylome analysis in human cortical neurons identifies novel gene pathways and drug targets for opioid use disorder

Sheila T Nagamatsu; Gregory Rompala; Yasmin L Hurd; Diana L Núñez-Rios; Janitza L Montalvo-Ortiz; Traumatic Stress Brain Research Group

doi:10.3389/fpsyt.2022.1078894

CpH methylome analysis in human cortical neurons identifies novel gene pathways and drug targets for opioid use disorder

Front Psychiatry. 2023 Jan 19:13:1078894. doi: 10.3389/fpsyt.2022.1078894. eCollection 2022.

Authors

Sheila T Nagamatsu^{1

2

3}, Gregory Rompala⁴, Yasmin L Hurd⁴, Diana L Núñez-Rios^{1

2

3}, Janitza L Montalvo-Ortiz^{1

2

3}; Traumatic Stress Brain Research Group

Collaborators

Traumatic Stress Brain Research Group:
Victor E Alvarez, David Benedek, Alicia Che, Dianne A Cruz, David A Davis, Matthew J Girgenti, Ellen Hoffman, Paul E Holtzheimer, Bertrand R Huber, Alfred Kaye, John H Krystal, Adam T Labadorf, Terence M Keane, Mark W Logue, Ann McKee, Brian Marx, Deborah Mash, Mark W Miller, Crystal Noller, Jm-O, William K Scott, Paula Schnurr, Thor Stein, Robert Ursano, Douglas E Williamson, Erika J Wolf, Keith A Young

Affiliations

¹ Division of Human Genetics, Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States.
² VA Connecticut (VA CT) Healthcare Center, West Haven, CT, United States.
³ Clinical Neurosciences Division, U.S. Department of Veterans Affairs National Center of Posttraumatic Stress Disorder, West Haven, CT, United States.
⁴ Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Abstract

Introduction: DNA methylation (DNAm), an epigenetic mechanism, has been associated with opioid use disorder (OUD) in preclinical and human studies. However, most of the studies have focused on DNAm at CpG sites. DNAm at non-CpG sites (mCpHs, where H indicates A, T, or C) has been recently shown to have a role in gene regulation and to be highly abundant in neurons. However, its role in OUD is unknown. This work aims to evaluate mCpHs in the human postmortem orbital frontal cortex (OFC) in the context of OUD.

Methods: A total of 38 Postmortem OFC samples were obtained from the VA Brain Bank (OUD = 12; Control = 26). mCpHs were assessed using reduced representation oxidative bisulfite sequencing in neuronal nuclei. Differential analysis was performed using the "methylkit" R package. Age, ancestry, postmortem interval, PTSD, and smoking status were included as covariates. Significant mCpHs were set at q-value < 0.05. Gene Ontology (GO) and KEGG enrichment analyses were performed for the annotated genes of all differential mCpH loci using String, ShinyGO, and amiGO software. Further, all annotated genes were analyzed using the Drug gene interaction database (DGIdb).

Results: A total of 2,352 differentially methylated genome-wide significant mCpHs were identified in OUD, mapping to 2,081 genes. GO analysis of genes with differential mCpH loci showed enrichment for nervous system development (p-value = 2.32E-19). KEGG enrichment analysis identified axon guidance and glutamatergic synapse (FDR 9E-4-2.1E-2). Drug interaction analysis found 3,420 interactions between the annotated genes and drugs, identifying interactions with 15 opioid-related drugs, including lofexidine and tizanidine, both previously used for the treatment of OUD-related symptoms.

Conclusion: Our findings suggest a role of mCpHs for OUD in cortical neurons and reveal important biological pathways and drug targets associated with the disorder.

Keywords: epigenetic; methylation; non-CpG site; opioid; orbitofrontal cortex; postmortem human brain.

Abstract

Grants and funding